These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1849 related items for PubMed ID: 23063375

  • 1. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [Abstract] [Full Text] [Related]

  • 2. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Keirns J.
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
    Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T.
    Clin Ther; 2015 May 01; 37(5):1031-44. PubMed ID: 25791612
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.
    Clin Drug Investig; 2013 Jan 01; 33(1):11-23. PubMed ID: 23208320
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
    Lee S, Gu N, Kim BH, Lim KS, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 May 01; 34(5):1160-9. PubMed ID: 22503212
    [Abstract] [Full Text] [Related]

  • 16. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.
    Clin Ther; 2009 Sep 01; 31(9):1992-2001. PubMed ID: 19843489
    [Abstract] [Full Text] [Related]

  • 17. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
    van Gelderen M, Tretter R, Meijer J, Dorrepaal C, Gangaram-Panday S, Brooks A, Krauwinkel W, Dickinson J.
    Int J Clin Pharmacol Ther; 2014 Aug 01; 52(8):693-701. PubMed ID: 24755125
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T, Rocha JF, Vaz-da-Silva M, Falcão A, Almeida L, Soares-da-Silva P.
    Clin Ther; 2011 Jun 01; 33(6):776-91. PubMed ID: 21704242
    [Abstract] [Full Text] [Related]

  • 19. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.
    Clin Drug Investig; 2013 Jun 01; 33(6):429-40. PubMed ID: 23625188
    [Abstract] [Full Text] [Related]

  • 20. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Feb 01; 34(2):482-94. PubMed ID: 22284902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.